



Saudi Food & Drug Authority (SFDA) Safety Communication

07/04/2020

SFDA Advises Continued Use of Angiotensin-Converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockers (ARBs) in Patients with COVID-19

SFDA is aware of the latest media reports that question whether certain medicines, such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), may worsen coronavirus disease 2019 (COVID-19). Currently, there is no evidence from clinical or epidemiological studies that establish a link between ACE inhibitors or ARBs and the worsening of COVID-19.

ACE inhibitors and ARBs are most commonly used to treat patients with hypertension, or heart failure or kidney disease. It is important that patients do not interrupt their treatment with ACE inhibitors or ARBs and there is no need to switch to other medicines. SFDA monitoring the situation closely and will review any new information that becomes available on this issue.

SFDA always recommends following the instructions in the patient information leaflet that available in the package of the medicinal product and warns against exceeding the dose of the medicine mentioned in the leaflet.

To look at all pharmaceutical products that are marketed in Saudi Arabia, you can simply do that by browsing the SFDA website or by using the Tameni app.

The SFDA urges healthcare professionals and patients to report Adverse Drug Reactions via any of the following contact information:

National Pharmacovigilance Center (NPC)
Saudi Food and Drug Authority-Drug sector
4904 Northern ring branch re- Hitteen District
Riyadh 13513 - 7148
Kingdom of Saudi Arabia
Reporting hotline: 19999
Email: npc.drug@sfda.gov.sa
Webpage: <http://ade.sfda.gov.sa>